For patients with no history of coronary artery disease (CAD), new research shows the use of CT-derived fractional flow reserve (FFR-CT) guided revascularizations after elective vascular surgery reduced myocardial infarction and all-cause death by 20 percent in comparison to standard care.
Can computed tomography-based fractional flow reserve (FFR-CT) assessment facilitate improved outcomes for patients after elective vascular surgery procedures?
For the observational study, recently published in the Journal of Vascular Surgery, researchers compared the use of preoperative coronary CT angiography (CTA), preoperative FFR-CT testing, postoperative coronary revascularization, and best medical therapy (BMT) in 288 patients versus 234 patients who had standard preoperative cardiac assessment and postoperative BMT. All patients in the cohort underwent elective aneurysm, carotid, or peripheral vascular surgery procedures, and had no known coronary artery disease (CAD), according to the study.
Preoperative FFR-CT testing revealed asymptomatic lesion-specific coronary ischemia in 65 percent of patients, including severe ischemia for 52 percent of patients and multivessel ischemia in 36 percent of the patients. The researchers noted that 103 patients had ischemia-targeted coronary revascularization one to three months after vascular surgery.
In comparison to patients who had standard post-op care, the study authors said five-year outcomes showed that post-op FFR-CT guided revascularization led to a 20 percent lower incidence of myocardial infarction (MI) (4 percent vs. 24 percent); a 27 percent lower incidence of major adverse cardiovascular events (MACEs) (20 percent vs. 47 percent); and a 20 percent lower incidence of all-cause deaths (16 percent vs. 36 percent).
“The remarkable reduction in death and major adverse cardiovascular events in the CTA-FFRCT group was associated with elective ischemia-targeted coronary revascularization in 36% of patients in addition to BMT following recovery from the vascular surgery procedure,” wrote lead study author Dainis K. Krievins, M.D., Ph.D., who is affiliated with the Department of Vascular Surgery at Pauls Stradins Clinical University Hospital in Riga, Latvia, and colleagues.
The study authors emphasized that current guidelines do not adequately address the impact of asymptomatic coronary ischemia in patients undergoing elective vascular surgery procedures.
“Current guideline recommendations to not diagnose and treat significant CAD in patients with (peripheral artery disease) PAD with no cardiac symptoms is remarkable, considering the limited level 1 evidence to support these recommendations and the knowledge that many, if not most, vascular surgery patients have silent coronary ischemia, which is a marker for MI and death,” maintained Krievins and colleagues.
While acknowledging the need for prospective, randomized trials, the researchers said the combination of FFR-CT assessment and coronary revascularization can have a substantial impact for patients with asymptomatic coronary ischemia.
“These data show that there is a role for coronary revascularization in the management of CAD in vascular surgery patients and that sole reliance on medical treatment and risk factor control has been insufficient,” noted Krievins and colleagues. “Although the diagnosis of silent coronary ischemia in our study was made preoperatively, the long-term benefit of fewer adverse coronary events and improved survival was achieved with postoperative coronary revascularization. It is possible that a strategy of postoperative diagnosis of coronary ischemia coupled with ischemia-targeted coronary revascularization may be equally effective.”
In regard to study limitations, the authors conceded the possibility of patient selection bias with the single-center, non-randomized nature of the research. Noting limited availability of coronary CTA for clinical research (one day a week) in contrast to elective vascular surgery procedures being performed five days a week, the researchers acknowledged that patients who met the criteria for the study but didn’t have access to coronary CTA imaging were included in the group that received usual care.
New Study Assesses Benefits of High-Resolution Photon-Counting for Computed Tomography Angiography
October 10th 2024Researchers found that ultra-high resolution photon-counting significantly enhanced visualization of small vessels and facilitated improved reduction of blooming artifacts for head and neck computed tomography angiography (CTA) scans.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Software for Enhancing CCTA Assessment of Atherosclerosis
October 1st 2024Through analysis of coronary computed tomography angiography (CCTA) images, the PlaqueIQ software provides quantification and classification of atherosclerosis, a common cause of myocardial infarction (MI) and ischemic stroke.
CT Study Links Pleural Effusion and Higher 30-Day Mortality Rates in Patients with COVID-19
October 1st 2024In a multicenter study of over 1,100 patients with COVID-19, pleural effusion was detected on CT scans in nearly a third of patients, who also had significantly higher ICU admission and 30-day mortality rates.